XTL Biopharmaceuticals Ltd
XTLB
Company Profile
Business description
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Contact
85 Medinat Hayehudim Street
Hertzlia4676670
ISRT: +972 542288897
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,920.20 | 1.50 | -0.02% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 69,342.03 | 1,132.93 | -1.61% |
| NZX 50 Index | 13,555.35 | 55.15 | -0.41% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,716.60 | 6.00 | 0.07% |
| SSE Composite Index | 4,112.11 | 0.34 | -0.01% |